Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-065609
Filing Date
2025-05-07
Accepted
2025-05-07 16:03:46
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q inab-20250331.htm   iXBRL 10-Q 1816975
2 EX-31.1 inab-ex31_1.htm EX-31.1 16068
3 EX-31.2 inab-ex31_2.htm EX-31.2 15996
4 EX-32.1 inab-ex32_1.htm EX-32.1 18944
5 GRAPHIC img240708105_0.jpg GRAPHIC 458370
  Complete submission text file 0000950170-25-065609.txt   8108243

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inab-20250331.xsd EX-101.SCH 1075144
70 EXTRACTED XBRL INSTANCE DOCUMENT inab-20250331_htm.xml XML 970502
Mailing Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118
Business Address EMPIRE STATE BUILDING 350 5TH AVENUE, SUITE 5330 NEW YORK NY 10118 (646) 600-6438
IN8BIO, INC. (Filer) CIK: 0001740279 (see all company filings)

EIN.: 825462585 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39692 | Film No.: 25921170
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)